268 related articles for article (PubMed ID: 27809913)
1. Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study.
Iughetti L; Tornese G; Street ME; Napoli F; Giavoli C; Antoniazzi F; Stagi S; Luongo C; Azzolini S; Ragusa L; Bona G; Zecchino C; Aversa T; Persani L; Guazzarotti L; Zecchi E; Pietropoli A; Zucchini S
Ital J Pediatr; 2016 Nov; 42(1):93. PubMed ID: 27809913
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study Italian cohort.
Iughetti L; Antoniazzi F; Giavoli C; Bona G; Aversa T; Greggio NA; Guazzarotti L; Minelli R; Perrone L; Persani L; Pozzobon G; Ragusa L; Stagi S; Tornese G; Zecchino C; Gallinari P; Zouater H; Fedeli P; Zucchini S
J Endocrinol Invest; 2021 Mar; 44(3):493-503. PubMed ID: 32557273
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of Omnitrope
Ferone D; Profka E; Gasco V; Ambrosio MR; Colao A; Di Somma C; Puxeddu E; Arnaldi G; Pagano C; Zecchi E; Pietropoli A; Beck-Peccoz P
J Endocrinol Invest; 2017 Jun; 40(6):669-678. PubMed ID: 28161880
[TBL] [Abstract][Full Text] [Related]
4. Safety and Effectiveness of Omnitrope®, a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years' Experience from the PATRO Children Study.
Pfäffle R; Bidlingmaier M; Kreitschmann-Andermahr I; Land C; Partsch CJ; Schwab KO; Sommer H; Backeljauw P; Kanumakala S; Loche S; Zouater H; Strasburger CJ
Horm Res Paediatr; 2020; 93(3):154-163. PubMed ID: 32814319
[TBL] [Abstract][Full Text] [Related]
5. Safety and Effectiveness of a Biosimilar Recombinant Human Growth Hormone in Children Requiring Growth Hormone Treatment: Analysis of Final Data from PATRO Children, an International, Post-Marketing Surveillance Study.
Loche S; Kanumakala S; Backeljauw P; Schwab KO; Lechuga-Sancho AM; Esmael A; Urosevic D; Boldea A; Zabransky M
Drug Des Devel Ther; 2024; 18():667-684. PubMed ID: 38454934
[TBL] [Abstract][Full Text] [Related]
6. Ten years with biosimilar rhGH in clinical practice in Sweden - experience from the prospective PATRO children and adult studies.
Lundberg E; Kriström B; Zouater H; Deleskog A; Höybye C
BMC Endocr Disord; 2020 Apr; 20(1):55. PubMed ID: 32349731
[TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of Omnitrope
Backeljauw P; Kanumakala S; Loche S; Schwab KO; Miller BS; Levy R; McCormick K; Zouater H; Zabransky M; Campbell K
Eur J Pediatr; 2022 Jun; 181(6):2367-2378. PubMed ID: 35275291
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of Omnitrope® in patients with growth hormone deficiency: snapshot analysis of PATRO Adults study in the Italian population.
Arosio M; Arnaldi G; Gasco V; Giavoli C; Puxeddu E; Vettor R; Ambrosio MR; Gallinari P; Zouater H; Fedeli P; Ferone D
J Endocrinol Invest; 2021 Feb; 44(2):327-337. PubMed ID: 32507990
[TBL] [Abstract][Full Text] [Related]
9. Safety and Effectiveness of Recombinant Human Growth Hormone in Children with Turner Syndrome: Data from the PATRO Children Study.
Backeljauw P; Kanumakala S; Loche S; Schwab KO; Pfäffle RW; Höybye C; Lundberg E; Battelino T; Kriström B; Giemza T; Zouater H
Horm Res Paediatr; 2021; 94(3-4):133-143. PubMed ID: 34350858
[TBL] [Abstract][Full Text] [Related]
10. Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope(®) in children requiring growth hormone treatment.
Pfäffle R; Schwab KO; Marginean O; Walczak M; Szalecki M; Schuck E; Zabransky M; Zucchini S
Ther Adv Endocrinol Metab; 2013 Feb; 4(1):3-11. PubMed ID: 23515245
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PATRO Adults).
Höybye C; Beck-Peccoz P; Murray RD; Simsek S; Stalla G; Strasburger CJ; Urosevic D; Zouater H; Johannsson G
Pituitary; 2021 Aug; 24(4):622-629. PubMed ID: 33742320
[TBL] [Abstract][Full Text] [Related]
12. Two-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age.
Schwarz HP; Walczak M; Birkholz-Walerzak D; Szalecki M; Nanu M; Woehling H; Schuck E
Adv Ther; 2016 Mar; 33(3):423-34. PubMed ID: 26886776
[TBL] [Abstract][Full Text] [Related]
13. PATRO children, a multi-center, non-interventional study of the safety and effectiveness of Omnitrope
Backeljauw P; Miller BS; Levy R; McCormick K; Zouater H; Zabransky M; Campbell K
J Pediatr Endocrinol Metab; 2021 Apr; 34(4):431-440. PubMed ID: 33647196
[TBL] [Abstract][Full Text] [Related]
14. No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study.
Beck-Peccoz P; Höybye C; Murray RD; Simsek S; Zabransky M; Zouater H; Stalla G
BMC Endocr Disord; 2019 Dec; 19(1):138. PubMed ID: 31829160
[TBL] [Abstract][Full Text] [Related]
15. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study.
Romer T; Saenger P; Peter F; Walczak M; Le Bouc Y; Khan-Boluki J; Berghout A
Horm Res; 2009; 72(6):359-69. PubMed ID: 19844125
[TBL] [Abstract][Full Text] [Related]
16. A follow-up study to monitor adult height among Spanish children with growth hormone deficiency who received biosimilar human recombinant growth hormone (Omnitrope®) during a phase III clinical trial.
Borrás Pérez V; López-Siguero JP; Martínez G; Corripio R; Fernández JM; Labarta JI; Ferrer M; Cabrinety N; Prieto P; Ramón-Krauel M; Bosch J; Espino R; Palla Garcia M; Rebollo FJ
Adv Ther; 2015 Feb; 32(2):148-56. PubMed ID: 25667132
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of the recombinant human growth hormone Omnitrope® in the treatment of Spanish growth hormone deficient children: results of a phase III study.
López-Siguero J; Borrás Pérez MV; Balser S; Khan-Boluki J
Adv Ther; 2011 Oct; 28(10):879-93. PubMed ID: 21948492
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope(®) for the treatment of adult patients with growth hormone deficiency.
Beck-Peccoz P; Minuto F; Leal-Cerro A; Zabransky M; Stalla G
Ther Adv Endocrinol Metab; 2012 Jun; 3(3):85-91. PubMed ID: 23148199
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Overall Safety of NutropinAq
Coutant R; Bosch Muñoz J; Dumitrescu CP; Schnabel D; Sert C; Perrot V; Dattani M
Front Endocrinol (Lausanne); 2021; 12():676083. PubMed ID: 34113318
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a new ready-to-use recombinant human growth hormone solution.
Romer T; Peter F; Saenger P; Starzyk J; Koehler B; Korman E; Walczak M; Wasik R; Ginalska-Malinowska M; Solyom E; Berghout A
J Endocrinol Invest; 2007; 30(7):578-89. PubMed ID: 17848841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
